Biogen Aktie

Biogen für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 789617 / ISIN: US09062X1037

<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
22.01.2018 03:21:14

WSJ : Sanofi Nears Deal To Buy Bioverativ For More Than $11.5 Bln

(RTTNews) - Sanofi SA (SNYNF, SNY) is nearing a deal to buy hemophilia drugmaker Bioverativ Inc. (BIVV) for more than $11.5 billion as the French drugmaker looks set to clinch a big deal while it braces for generic competition for its top-selling product, the Wall Street Journal reported citing people familiar with the matter

A deal, which could be announced as soon as Monday, would value the former Biogen Inc. unit at $105 a share. The price would represent a 63% premium to where Bioverativ closed trading Friday. It is possible the talks could fall apart before a deal is reached, the Journal reported.

Analysen zu Sanofi S.A.mehr Analysen

30.05.25 Sanofi Buy UBS AG
30.05.25 Sanofi Neutral JP Morgan Chase & Co.
28.05.25 Sanofi Buy Jefferies & Company Inc.
16.05.25 Sanofi Buy Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
08.05.25 Sanofi Neutral JP Morgan Chase & Co.
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Biogen Inc 114,35 -1,51% Biogen Inc
Sanofi S.A. (spons. ADRs) 43,00 -6,93% Sanofi S.A. (spons. ADRs)
Sanofi S.A. 87,03 -5,12% Sanofi S.A.